Photocure ASA Reports Impressive Growth in Q3
OSLO, Norway – Photocure ASA (OSE: PHO) has shared remarkable financial results for the third quarter of 2025, showcasing a significant increase in revenues from its flagship products, Hexvix and Cysview. The company reported revenues of NOK 134.1 million, marking a robust growth compared to NOK 120.1 million in the same quarter last year. Moreover, an EBITDA of NOK 10.2 million was observed, climbing from NOK 5.0 million in Q3 2024.
Positive Outlook for Revenue Growth
President and CEO Dan Schneider expressed his optimism, stating, "Photocure delivered another strong quarter, extending our track record of double-digit topline revenue growth with positive EBITDA. We continued to execute with discipline in parallel with advancing new growth initiatives that further amplify our central role in precision diagnostics for bladder cancer." This growth trajectory reflects the company’s strategic efforts and commitment to enhance bladder cancer detection and treatment.
Expansion of Blue Light Cystoscopy
In Q3 2025, Photocure has actively pursued plans to broaden the use of blue light cystoscopy (BLC) technology. The company successfully installed 14 new Saphira towers in the United States, consisting of 7 new accounts and 7 upgrades to existing towers. The increasing demand led ForTec to acquire 6 additional BLC towers, raising the total number of mobile BLC towers to 24. At the end of the quarter, Photocure had 373 active accounts in the U.S., a 23% increase compared to the previous quarter.
Innovative Partnerships
An exciting development for Photocure was the announcement of a partnership with Intelligent Scopes Corporation (ISC), aiming to develop AI software designed to support physicians in real-time during BLC procedures. This innovative approach is anticipated to enhance early-stage bladder cancer detection and improve surgical outcomes. Schneider said, "Together, Photocure and ISC intend to pursue FDA clearance for the AI software compatible with any BLC system. Our partnership represents a step toward clinical adoption, driving operational leverage for continued shareholder value growth."
Strategic Market Insights and Future Directions
Photocure is optimistic about sustained revenue growth driven by expanded mobile BLC services, increased utilization of its rigid kit, and continuous upgrades throughout the year. The company is well-positioned in a market that is increasingly focusing on early detection and personalized treatment of bladder cancer. Schneider remarked, "The tailwinds from recently approved therapeutics for non-muscle invasive bladder cancer (NMIBC) are raising awareness around early detection, further validating our core processes and procedures."
Key Factors Influencing Growth
Several upcoming catalysts could further propel growth at Photocure. These include potential reimbursement developments, the reintroduction of innovative BLC solutions into the market, the entry of new manufacturers, and the possibility of FDA reclassification supporting BLC. Each of these factors presents an opportunity to enhance patient access and stimulate adoption rates.
Financial Snapshot and Future Projections
In terms of overall financial performance, Photocure reported total revenues of NOK 135.0 million, up from NOK 120.2 million previously. The EBIT recorded was NOK 2.9 million against the prior year's negative EBIT. The company’s strong cash position is reflected with NOK 247.8 million in cash and cash equivalents at the quarter's end.
Further Opportunities
Schneider also highlighted the potential milestone payment from its licensing agreement with Asieris regarding Cevira, contingent upon regulatory approval in China. This could be a significant boon for Photocure and further enhance its financial standing in the upcoming period.
Contact and Company Information
For more details, please contact: Dan Schneider, President and CEO; Erik Dahl, Chief Financial Officer; andPriyam Shah, Vice President of Investor Relations. Photocure ASA specializes in innovative solutions for bladder cancer diagnosis and treatment. Founded in Oslo, Norway, the company is focused on improving patient outcomes through its patented technologies.
Frequently Asked Questions
What recent financial results did Photocure ASA report?
Photocure ASA reported revenues of NOK 134.1 million and an EBITDA of NOK 10.2 million for Q3 2025.
What strategic initiatives is Photocure ASA pursuing?
The company is expanding its blue light cystoscopy (BLC) offerings and developing AI software with Intelligent Scopes Corporation.
How is Photocure ASA positioning itself in the bladder cancer market?
Photocure is focusing on early detection and personalized management of bladder cancer, leveraging innovative technologies and partnerships.
What growth factors are anticipated for Photocure ASA?
Projected growth is linked to expanded mobile BLC services, ongoing equipment upgrades, and new therapeutic developments.
Who can be contacted for more information about Photocure ASA?
Inquiries can be directed to Dan Schneider, President and CEO, or Erik Dahl, CFO, at the company's headquarters.
